肝移植拔除T管后胆漏的超声介入治疗

目的探讨超声引导下置管引流在肝移植拔除T管后胆漏中的价值,并与其他处理方法作比较。方法2001年8月至2005年3月肝移植行胆管端端吻合或胆肠吻合放置T管患者76例,拔除T管后发生胆漏9例,其中8例患者行超声引导下置管引流,男性7例,女性1例,年龄22-59岁,平均46.7岁。穿刺置管引流术方法为确定穿刺点,在超声引导下采用Seldinger法徒手操作,18G穿刺针穿入积液内,观察到针尖进入积液区后拔出针芯,见液体流出或抽出液体后放入导丝,退出穿刺针放置带内套针的7F直通管,导管进入积液内退出内套针和导丝,局部固定包敷引流管。结果8例患者拔除T管后分别出现剧烈腹痛、发烧、大汗淋漓等症状,超声检查发现均有盆腔积液,积液最大深度范围为3～7cm。8例超声引导下置管引流均一次成功,引流出淡黄色或金黄色胆汁,1d内症状均迅速改善或消失。5～10d后见管内无引流液后拔管,无并发症发生。结论超声引导下置管引流对肝移植拔除T管后胆漏的治疗是安全、有效的,具有重要价值。     

印度新专利法的实行对医药企业的影响

印度和我国一样都是发展中国家,人口众多,在医药领域既有很多相似之处,又存在激烈竞争:首先,从地理、人口、经济发展等方面看,中印两国国情比较相近,两国的制药产业也有惊人的相似之处(成本低廉,药品可获得性高);大部分企业仍处于低水平重复仿制阶段;研发力量较为薄弱,仿制药比     

新发涂阳肺结核患者发现延误对比分析

肺结核病传染源自开始出现症状至确诊接受治疗,这一阶段是向周围人群传播结核病的危险时期,因而,及时发现肺结核病传染源,对于控制结核病的传播具有十分重要的意义。为了解和掌握新发涂阳肺结核病人的发现延误情况,我们分别于2001、2006年进行了专题调查,现将资料对比分析如下。     

IL‐27 improves adoptive CD8+ T cells’ antitumor activity via enhancing cell survival and memory T cell differentiation

IL‐27 is an anti‐inflammatory cytokine that triggers enhanced antitumor immunity, particularly cytotoxic T lymphocyte responses. In the present study, we sought to develop IL‐27 into a therapeutic adjutant for adoptive T cell therapy using our well‐established models. We have found that IL‐27 directly improved the survival status and cytotoxicity of adoptive OT‐1 CD8⁺ T cells in vitro and in vivo. Meanwhile, IL‐27 treatment programs memory T cell differentiation in CD8⁺ T cells, characterized by upregulation of genes associated with T cell memory differentiation (T‐bet, Eomes, Blimp1, and Ly6C). Additionally, we engineered the adoptive OT‐1 CD8⁺ T cells to deliver IL‐27. In mice, the established tumors treated with OT‐1 CD8⁺ T‐IL‐27 were completely rejected, which demonstrated that IL‐27 delivered via tumor antigen–specific T cells enhances adoptive T cells’ cancer immunity. To our knowledge, this is the first application of CD8⁺ T cells as a vehicle to deliver IL‐27 to treat tumors. Thus, this study demonstrates IL‐27 is a feasible approach for enhancing CD8⁺ T cells’ antitumor immunity and can be used as a therapeutic adjutant for T cell adoptive transfer to treat cancer.     

Comparison of the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma: a retrospective cohort study

BackgroundThere is lack of studies on sequential regorafenib after sorafenib and lenvatinib treatment failure in patients with unresectable hepatocellular carcinoma (HCC). This study was to explore the safety and prognosis of sequential regorafenib after sorafenib and lenvatinib failure in HCC patients.MethodsThis study was a retrospective, real-world study that included 50 HCC patients who received sequential regrafinib after sorafenib and lenvatinib failure. The safety and prognosis of two groups were compared.ResultsThe incidence of all grade and III/IV adverse events were 68% and 24%. According to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 and modified (m) RECIST standards, the objective response rates (ORRs) after receiving regorafenib were 14.0% and 22.0%, respectively. The disease control rates (DCRs) were 62.0% and 60.0%, respectively. Based on different first-line targeted drugs, 50 patients were divided into sorafenib (n=22) and lenvatinib group (n=28). There was no differences between two groups except age and bilirubin. And there was no differences in other treatments before or after regorafenib. The baseline between two groups was basically same and had good comparability. There was no difference in incidence of all grade and III/IV adverse events, ORR and DCR between two groups (P>0.05). On long-term prognosis, total overall survival (TOS) in sorafenib and lenvatinib group were 23.0 (95% CI: 15.1–30.9) vs. 29.7 (95% CI: 21.4–38.1) months. The difference was statistically significant (P=0.041). Besides, regorafenib overall survival (ROS) in sorafenib and lenvatinib group were 11.7 (95% CI: 7.1–16.3) vs. 15.9 (95% CI: 8.3–23.5) months. The difference was statistically significant ( P=0.045). The regorafenib progression-free survival (RPFS) was 5.6 (95% CI: 1.9–9.2) vs. 8.0 (95% CI: 5.1–10.9) months in sorafenib and lenvatinib group, respectively, and difference was not statistically significant (P=0.380).ConclusionsRegorafenib is an effective drug for second-line treatment of HCC, with fewer severe adverse events, ORR and DCR was 14–22% and 62–60%, respectively. Both TOS and ROS in lenvatinib group were better than those in sorafenib group. For HCC patients whose first-line targeted drug is lenvatinib, it is safe and effective to accept regorafenib after disease progresses.     

Clinical application of metagenomic next‐generation sequencing technology in the diagnosis and treatment of pulmonary infection pathogens: A prospective single‐center study of 138 patients

IntroductionRapid and accurate pathogen identification is essential for the treatment of pneumonia. Metagenomic next‐generation sequencing (mNGS) is a newly developed technology to obtain microbial nucleic acid sequence information quickly, efficiently, and without bias.MethodsWe performed shotgun metagenomic next‐generation sequencing (mNGS) of bronchoalveolar lavage fluid (BALF) for pathogen identification in pneumonia in a prospective study with 138 patients from a single center. We compared the results of mNGS with standard methods including culture, staining, and targeted PCR and evaluated the clinical applicability of mNGS.ResultsMost of the patients (128/138, 92.75%) were cured or improved. One patient (1/138, 0.72%) died because of acute gastrointestinal bleeding, and 9 patients (9/138, 6.52%) showed no improvement. mNGS identified more bacteria (53 versus 27), fewer fungi (8 versus 31), and more viruses (16 versus 1) than standard methods. In total, treatment in 34 out of 138 cases (24.64%) was adjusted and optimized because of mNGS results. Positive mNGS results contributed to a definitive diagnosis in 23 cases (16.67%), which helped guide treatment decision by either adjusting the antibiotics without de‐escalation or continuing the empirical treatment. mNGS also confirmed no active infection in 11 cases (7.97%) allowed for antibiotic de‐escalation.ConclusionThis prospective clinical study evaluated the clinical utility of mNGS for the diagnosis of pneumonia and showed that mNGS of BALF provides valuable information for effective treatment.     

The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis: a clinical retrospective analysis

BackgroundThe basic platelet counts of schistosomiasis patients are low. If it does not meet the requirements for chemotherapy, the patient’s treatment will not be carried out, which directly affects their prognosis. Therefore the impact of treatment on platelet counts is critically important. The effects of bevacizumab plus oxaliplatin-based chemotherapy and bevacizumab plus irinotecan-based chemotherapy regimens on platelets are different but have not been determined. In order to find a more suitable plan for metastatic colorectal cancer (mCRC) patients with a history of schistosomiasis, we conducted a retrospective analysis of mCRC patients and evaluated the impact of bevacizumab on their platelets.MethodsThe medical records of all mCRC patients with a history of schistosomiasis who received oxaliplatin-based chemotherapy or irinotecan-based chemotherapy as first-line treatment for no less than 4 cycles, with or without bevacizumab from September 1, 2017, to June 30, 2019, in Kunshan Hospital were reviewed. Six-month cumulative incidence rates of splenomegaly and thrombocytopenia of chemotherapy with and without bevacizumab groups, oxaliplatin-based chemotherapy with and without bevacizumab groups, irinotecan-based chemotherapy with and without bevacizumab groups were compared from the first cycle until the completion of chemotherapy using Kaplan-Meier analysis and Log-rank test.ResultsEvaluable splenic enlargement and thrombocytopenia results were obtained from 153 mCRC patients. The 6-month cumulative incidence rates of splenomegaly (23.3% vs. 55%; P=0.01) and that of thrombocytopenia (43.8% vs. 57.5%; P=0.40) were lower in the bevacizumab group than the non-bevacizumab group, however there were no statistical differences for the rates of thrombocytopenia. For patients treated with oxaliplatin, the rates of splenomegaly (19.5% vs. 66.7%; P=0.01) and thrombocytopenia (31.7% vs. 77.2%; P=0.02) were lower in the bevacizumab-treated cohort than that in the non-bevacizumab cohort. When stratified for irinotecan, there were no statistical differences in the frequency of splenomegaly between the two groups. However, the rates of thrombocytopenia were higher in the bevacizumab-treated cohort than that in the non-bevacizumab cohort (59.4% vs. 8.7%; P=0.01).ConclusionsThe bevacizumab plus oxaliplatin-based chemotherapy regimen is safer for mCRC patients with a history of schistosomiasis, especially for patients with a lower platelet count.     

1例X连锁型视网膜色素变性家系的分子遗传学研究

目的 对1例来自云南省的X连锁型视网膜色素变性家系进行相关分子遗传学研究.方法 在本研究小组前期工作中对该家系已初步确定的X连锁型遗传位点--RP2和RP3处选取具有高信息量的9个微卫星位标进行精细单倍型分析.在定位的候选基因RP3基因即RPGR基因上,使用构象敏感凝胶电泳(conformation sensitive gel electrophoresis, CSGE)的方法对其1～14号外显子进行突变筛选的同时对已有报道的突变热点区--外显子ORF15进行直接测序以寻找致病突变.结果 通过精细定位扫描及相关单倍型分析,将该例家系的致病基因定位在RP3位点.RPGR基因1～14号外显子经CSGE的方法进行突变筛选,未发现有异常电泳条带;通过直接对突变热点区外显子ORF15的测序,在该例家系中检测到1个在国内外均有报道的热点突变:g.ORF15 483_484delGA.结论 g.ORF15 483_484delGA移码突变导致了该家系产生X连锁型视网膜色素变性.     

急性缺氧条件下氰化钠中毒对大鼠脑组织能量代谢的影响

目的探讨急性高原缺氧条件下氰化钠中毒对大鼠脑组织能量代谢的影响。方法雄性sD大鼠,分为平原组和高原组。平原组动物在本地常规实验室内处理。高原组动物放置于模拟4000m海拔高度的低压舱内3d后开始实验。为大鼠腹腔注射氰化钠（NaCN）3．6mg／kg染毒,于0、0．5、1、2、4、6h6个时相点麻醉后断头取脑。以干湿质量法测定脑组织含水量,伊文思蓝法检测脑组织血管通透性,高效液相色谱（high performance liquid chromatography,HPLC）法测定大鼠脑纹状体和海马组织腺苷三磷酸（adenosine triphosphate,ATP）、腺苷二磷酸（adenosine diphosphate,ADP）和腺苷-磷酸（adenosine monophosphate,AMP）含量。结果与平原组比较,高原缺氧环境氰化钠中毒大鼠脑组织含水量增加,纹状体和海马组织ATP和ADP含量减少,AMP含量增加。结论高原缺氧可导致大鼠脑组织腺苷酸能量代谢障碍,缺氧条件下氰化钠中毒可进一步加重脑组织能量代谢障碍,同时脑水肿也进一步加重。